Stay informed with our
free newsletters

Technology Transfer for Manufacturing of COVID-19 Recombinant Protein-based Vaccine to Vietnam

Shionogi & Co., Ltd. (hereafter "Shionogi") announced that Shionogi is in discussions with the Socialist Republic of Vietnam (hereinafter "Vietnam") regarding technology transfer for the manufacturing of the COVID-19 recombinant protein-based vaccine that we are developing in Japan.

Shionogi recognizes Japan's global role in addressing this pandemic by contributing to effective countermeasures worldwide, which is fully aligned with our own mission as a company dedicated to the control of infectious diseases. Therefore, we are proceeding with discussions regarding this technology transfer to Vietnam. Yesterday, it was reported that an agreement had already been concluded in this regard between Shionogi and a Vietnamese company, but it is still under discussion and a final detailed agreement has not yet been reached.

This matter does not affect Shionogi’s vaccine development and production planning in Japan

mRNA: Therapeutics and Global Markets

mRNA: Therapeutics and Global Markets

Download free sample pages

Source: Shionogi
Date: Jul 28, 2021


Share this news: